SPEXZ Stock Overview
A clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Spexis AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 0.054 |
| 52 Week High | CHF 0.35 |
| 52 Week Low | CHF 0.031 |
| Beta | 0.19 |
| 1 Month Change | 0% |
| 3 Month Change | -1.10% |
| 1 Year Change | n/a |
| 3 Year Change | -97.11% |
| 5 Year Change | n/a |
| Change since IPO | -99.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| SPEXZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -3.5% | 0.3% |
| 1Y | n/a | -23.5% | 6.6% |
Return vs Industry: Insufficient data to determine how SPEXZ performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how SPEXZ performed against the UK Market.
Price Volatility
| SPEXZ volatility | |
|---|---|
| SPEXZ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SPEXZ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine SPEXZ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 50 | Jeff Wager | spexisbio.com |
Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase 1 development stage to treat Pseudomonas aeruginosa infection in people with CF; EBX-002 for non-tuberculous mycobacterial lung infections; Balixafortide for oncology and non-oncology indications; New CXCR4 for treating orphan and hematological malignancies, and non-oncology indications; and Outer Membrane Protein Targeting Antibiotic BamA and lipopolysaccharide transport protein A programs. Spexis AG is headquartered in Allschwil, Switzerland.
Spexis AG Fundamentals Summary
| SPEXZ fundamental statistics | |
|---|---|
| Market cap | CHF 2.03m |
| Earnings (TTM) | -CHF 19.62m |
| Revenue (TTM) | CHF 595.35k |
3.4x
P/S Ratio-0.1x
P/E RatioIs SPEXZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPEXZ income statement (TTM) | |
|---|---|
| Revenue | CHF 595.35k |
| Cost of Revenue | CHF 0 |
| Gross Profit | CHF 595.35k |
| Other Expenses | CHF 20.21m |
| Earnings | -CHF 19.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,295.35% |
| Debt/Equity Ratio | 222.4% |
How did SPEXZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/21 20:36 |
| End of Day Share Price | 2024/07/24 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Spexis AG is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christian Orquera | First Berlin Equity Research GmbH |